ValuEngine lowered shares of Insys Therapeutics (NASDAQ:INSY) from a buy rating to a hold rating in a research note issued to investors on Thursday.
Separately, Zacks Investment Research upgraded Insys Therapeutics from a sell rating to a hold rating in a report on Thursday, October 11th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $7.67.
Shares of Insys Therapeutics stock opened at $4.91 on Thursday. Insys Therapeutics has a 52 week low of $4.80 and a 52 week high of $14.00.
Institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning bought a new position in Insys Therapeutics in the third quarter worth $153,000. Millennium Management LLC bought a new position in Insys Therapeutics in the second quarter worth $1,232,000. BNP Paribas Arbitrage SA raised its holdings in Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares in the last quarter. BlackRock Inc. raised its holdings in Insys Therapeutics by 7.9% in the second quarter. BlackRock Inc. now owns 2,637,505 shares of the specialty pharmaceutical company’s stock worth $19,096,000 after purchasing an additional 193,740 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its holdings in Insys Therapeutics by 54.4% in the third quarter. Panagora Asset Management Inc. now owns 285,646 shares of the specialty pharmaceutical company’s stock worth $2,879,000 after purchasing an additional 100,637 shares in the last quarter. Institutional investors and hedge funds own 17.22% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Read More: Buyback
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.